

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in managing and understanding... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-2092/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-2092" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in managing and understanding pyoderma gangrenosum" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in managing and understanding pyoderma gangrenosum.">
            <meta name="og:description" content="Read the latest article version by Josh Fletcher, Raed Alhusayen, Afsaneh Alavi, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21847">
            <meta name="article-id" content="19909">
            <meta name="dc.title" content="Recent advances in managing and understanding pyoderma gangrenosum">
            <meta name="dc.description" content="Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG.">
            <meta name="dc.subject" content="Pyoderma Gangrenosum">
            <meta name="dc.creator" content="Fletcher, Josh">
            <meta name="dc.creator" content="Alhusayen, Raed">
            <meta name="dc.creator" content="Alavi, Afsaneh">
            <meta name="dc.date" content="2019/12/12">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19909.1">
            <meta name="dc.source" content="F1000Research 2019 8:2092">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Pyoderma Gangrenosum">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/12/12">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="2092">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19909.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-2092">
            <meta name="citation_title" content="Recent advances in managing and understanding pyoderma gangrenosum">
            <meta name="citation_abstract" content="Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG.">
            <meta name="citation_description" content="Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG.">
            <meta name="citation_keywords" content="Pyoderma Gangrenosum">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Josh Fletcher">
            <meta name="citation_author_institution" content="Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada">
            <meta name="citation_author" content="Raed Alhusayen">
            <meta name="citation_author_institution" content="Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada">
            <meta name="citation_author_institution" content="Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada">
            <meta name="citation_author" content="Afsaneh Alavi">
            <meta name="citation_author_institution" content="Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada">
            <meta name="citation_author_institution" content="Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, M5S 1B2, Canada">
            <meta name="citation_publication_date" content="2019/12/12">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="2092">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19909.1">
            <meta name="citation_firstpage" content="2092">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-2092/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-2092.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21847 /> <input type=hidden id=articleId name=articleId value=19909 /> <input type=hidden id=xmlUrl value="/articles/8-2092/v1/xml"/> <input type=hidden id=xmlFileName value="-8-2092-v1.xml"> <input type=hidden id=article_uuid value=0659ff69-fbdf-4bd9-b4d7-6da48d1991b8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in managing and understanding pyoderma gangrenosum"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19909.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19909.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-2092"
  },
  "headline": "Recent advances in managing and understanding pyoderma gangrenosum",
  "datePublished": "2019-12-12T11:00:13",
  "dateModified": "2019-12-12T11:00:13",
  "author": [
    {
      "@type": "Person",
      "name": "Josh Fletcher"
    },    {
      "@type": "Person",
      "name": "Raed Alhusayen"
    },    {
      "@type": "Person",
      "name": "Afsaneh Alavi"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-2092/v1",
            "name": "Recent advances in managing and understanding pyoderma gangrenosum"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in managing and understanding pyoderma gangrenosum </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21847 data-id=19909 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19909.1" data-recommended="" data-doi="10.12688/f1000research.19909.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-2092/v1/pdf?article_uuid=0659ff69-fbdf-4bd9-b4d7-6da48d1991b8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19909-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19909-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19909-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Fletcher J, Alhusayen R and Alavi A. Recent advances in managing and understanding pyoderma gangrenosum [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2092 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19909.1" target=_blank>https://doi.org/10.12688/f1000research.19909.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19909-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19909 id=track-article-signin-19909 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19909?target=/articles/8-2092/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21847 /> <input name=articleId type=hidden value=19909 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in managing and understanding pyoderma gangrenosum</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:josh.fletcher@mail.utoronto.ca" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Josh Fletcher</span></a><a href="https://orcid.org/0000-0002-1501-8401" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1501-8401</div><sup>1</sup>,&nbsp;</span><span class="">Raed Alhusayen<sup>1,2</sup>,&nbsp;</span><span class="">Afsaneh Alavi<sup>1,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:josh.fletcher@mail.utoronto.ca" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Josh Fletcher</span></a><a href="http://orcid.org/0000-0002-1501-8401" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1501-8401</div><sup>1</sup>,&nbsp;</span><span class="">Raed Alhusayen<sup>1,2</sup>,&nbsp;</span><span class="">Afsaneh Alavi<sup>1,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 12 Dec 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19909.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada<br/> <sup>2</sup> Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada<br/> <sup>3</sup> Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, M5S 1B2, Canada<br/> <p> <div class=margin-bottom> Josh Fletcher <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Raed Alhusayen <br/> <span>Roles: </span> Writing  Review & Editing </div> <div class=margin-bottom> Afsaneh Alavi <br/> <span>Roles: </span> Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61322-57771></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=61321-57772></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Pyoderma Gangrenosum </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Josh Fletcher (<a href="mailto:josh.fletcher@mail.utoronto.ca">josh.fletcher@mail.utoronto.ca</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Josh Fletcher </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Fletcher J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Fletcher J, Alhusayen R and Alavi A. Recent advances in managing and understanding pyoderma gangrenosum [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2092 (<a href="https://doi.org/10.12688/f1000research.19909.1" target=_blank>https://doi.org/10.12688/f1000research.19909.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 12 Dec 2019, <b>8</b>(F1000 Faculty Rev):2092 (<a href="https://doi.org/10.12688/f1000research.19909.1" target=_blank>https://doi.org/10.12688/f1000research.19909.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 12 Dec 2019, <b>8</b>(F1000 Faculty Rev):2092 (<a href="https://doi.org/10.12688/f1000research.19909.1" target=_blank>https://doi.org/10.12688/f1000research.19909.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e176>Introduction</h2><p class="" id=d14105e179>Pyoderma gangrenosum (PG) is a rare auto-inflammatory ulcerative dermatosis with an overall incidence of 5.8 per 100,000 individuals and an increased mortality rate when compared with the general population<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. However, given the lack of gold standard for diagnosis, the exact prevalence has yet to be elucidated since PG is commonly under- and over-diagnosed. PG is classified as a neutrophilic dermatosis because of a predominant neutrophilic inflammatory infiltrate in the lesions<sup><a href="#ref-3">3</a></sup>. The pathophysiology of PG is not completely understood and is thought to be multifactorial, involving both the innate and adaptive immune system and having a genetic influence<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>.</p><p class="" id=d14105e200>There is no widely accepted gold standard treatment in the management of PG. Proper analgesia, wound care, and compression therapy are all important tenets in the management of PG. Both topical and systemic therapy can be used, and choice of therapy is dependent on numerous factors, including the number of lesions, size, location, comorbid systemic disease, side effects of the medications, and patient preferences<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d14105e207>This review will summarize new advances in the pathophysiology, diagnosis, and management of PG in order to assist physicians in better understanding and managing PG and ultimately improving patient care.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e213>Pathophysiology</h2><p class="" id=d14105e216>The pathophysiology of PG is poorly understood and is thought to involve adaptive and innate immune system dysregulation, neutrophilic abnormalities (chemotaxis, adhesion, and trafficking), abnormal phagocytosis, and genetics<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d14105e223>There is increasing evidence in the literature that supports an immunologic etiology for PG. In addition, genetic disorders that alter the immune system are associated with PG<sup><a href="#ref-6">6</a></sup> and multiple novel therapeutic targets have been explored. These are described in more detail below (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21847/8545b83a-a9ba-4a57-9b26-c1573f1536e8_figure1.gif"><img alt="8545b83a-a9ba-4a57-9b26-c1573f1536e8_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21847/8545b83a-a9ba-4a57-9b26-c1573f1536e8_figure1.gif"></a><div class=caption><h3>Figure 1. Pathophysiology of pyoderma gangrenosum.</h3></div></div><div class=section><a name=d14105e247 class=n-a></a><h3 class=section-title>Neutrophil dysfunction</h3><p class="" id=d14105e252>The abundance of neutrophils in the histopathology of PG has been reported in typical untreated lesions. Histologic analysis of PG lesions demonstrates dermal edema, neutrophilic abscesses, and suppurative inflammation in the dermis that can reach the underlying subcutaneous fat<sup><a href="#ref-6">6</a></sup>. This is also evident in PGs association with other disorders related to neutrophilic dysfunction, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), seronegative arthritis, hematologic disorders, and malignancies such as acute myeloid leukemia (AML)<sup><a href="#ref-4">4</a>,<a href="#ref-7">7</a></sup>. Interleukin-6 (IL-6), a pro-inflammatory cytokine that plays a role in activation and accumulation of neutrophils, has been found to be elevated in PG lesions<sup><a href="#ref-8">8</a></sup>. Interestingly, some studies have shown PG lesions to be related to defects in adhesion and function of neutrophils, suggesting a multifactorial pathogenesis<sup><a href="#ref-7">7</a></sup>.</p></div><div class=section><a name=d14105e276 class=n-a></a><h3 class=section-title>The role of genetics</h3><p class="" id=d14105e281>Genetics play a role in the pathogenesis of PG, best exemplified by the PG-associated genetic syndromes. The specific mutations that give rise to PG-associated genetic syndromes are all associated with a pro-inflammatory state. Such syndromes and their associated gene mutations are listed in <a href="#T1">Table 1</a><sup><a href="#ref-4">4</a></sup>. For example, PAPA (pyogenic arthritis, PG, and acne) syndrome presents as sterile arthritis in childhood, severe cystic acne, pathergy, and recurrent ulcerations. The underlying mutation in PAPA syndrome leads to uncontrolled production of IL-1, thus leading to auto-inflammation<sup><a href="#ref-9">9</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Pyoderma gangrenosum (PG)-associated genetic syndromes and their specific gene mutations<sup><a href="#ref-4">4</a></sup>.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below id=T1-no-row-shading><a name=T1-no-row-shading class=n-a></a><thead><a name=d14105e311 class=n-a></a><tr><a name=d14105e313 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e315 class=n-a></a>Acronym</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e318 class=n-a></a>PG-associated syndrome</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e321 class=n-a></a>Gene mutation</th></tr></thead><tbody><a name=d14105e326 class=n-a></a><tr><a name=d14105e328 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e330 class=n-a></a>PAPA </td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e333 class=n-a></a>Pyogenic arthritis, PG, acne</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e336 class=n-a></a><i>PSTPIP1</i></td></tr><tr><a name=d14105e341 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e343 class=n-a></a>PASH </td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e346 class=n-a></a>PG, acne, suppurative hidradenitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e349 class=n-a></a><i>PSTPIP1, NCSTN</i></td></tr><tr><a name=d14105e354 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e356 class=n-a></a>PASS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e359 class=n-a></a>PG, acne conglobata, suppurative hidradenitis, seropositive<br class=br>spondyloarthropathies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e364 class=n-a></a>N/A</td></tr><tr><a name=d14105e368 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e370 class=n-a></a>PAPASH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e373 class=n-a></a>Pyogenic arthritis, PG, acne, suppurative hidradenitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e376 class=n-a></a><i>PSTPIP1</i></td></tr><tr><a name=d14105e381 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e383 class=n-a></a>PsAPASH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e386 class=n-a></a>Psoriatic arthritis, PG, acne, suppurative hidradenitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e389 class=n-a></a>N/A</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=TFN1 class=n-a></a><p id=d14105e399> N/A, not available; NCSTN, codes for nicastrin, a protein essential for chemical signaling pathways and for normal immune system functioning; PSTPIP1, proline-serine-threonine phosphatase-interacting protein 1.</p></div></div></div><p class="" id=d14105e405>Methylene tetrahydrofolate reductase (MTHFR) is an enzyme that assists in the conversion of homocysteine to methionine. Mutations lead to increased levels of homocysteine, resulting in a pro-inflammatory state. Enzymatic co-factors include folic acid, vitamin B<sub>6</sub>, and vitamin B<sub>12</sub>. There are cases of PG associated with this mutation in the literature, improved with vitamin B treatment<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d14105e418>There are some familial cases of PG in the literature. Three case reports in the pediatric population describe familial PG in both the setting and absence of systemic disease<sup><a href="#ref-10">10</a><a href="#ref-12">12</a></sup>. Other case reports describe the development of PG in family members after abdominal surgery and trauma<sup><a href="#ref-13">13</a></sup>. In addition, there are familial cases of PG-associated genetic syndromes in the literature<sup><a href="#ref-14">14</a></sup>. These case reports support the role of genetics in the pathogenesis of PG.</p></div><div class=section><a name=d14105e437 class=n-a></a><h3 class=section-title>The innate immune system</h3><p class="" id=d14105e442>Current research is continuing to identify newand confirm already-knowncytokines and signaling cascades involved in the pathogenesis of PG. The innate immune system signaling pathways, pattern recognition receptor (PRR) pathways (which are associated with autoimmune diseases such as IBD and RA), and Janus kinase (JAK) 13 and signal transducer and activator of transcription (STAT) pathways were upregulated in lesional skin compared with non-lesional skin in patients with PG<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. In comparisons of lesional skin of individuals with classic ulcerative PG and PG, acne, and suppurative hidradenitis (PASH) syndrome, both showed overexpression of IL-1, tumor necrosis factor alpha (TNF), IL-17, endothelial- and leukocyte-selectin, and chemokines IL-8, CXCL16, and RANTES<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. Matrix metalloproteinases, a group of enzymes involved in tissue damage, were overexpressed as well<sup><a href="#ref-7">7</a></sup>. Biopsies of pre-lesional PG (papules that eventually ulcerated) showed CD3<sup>+</sup> infiltrates and increased inflammatory cytokines, whereas PG lesions showed significant overexpression of IL-1, IL-1, IL-6, IL-8, and IL-36<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>.</p></div><div class=section><a name=d14105e474 class=n-a></a><h3 class=section-title>The adaptive immune system</h3><p class="" id=d14105e479>The adaptive immune system is also thought to play a role in PG given that medications interfering with T-cell function and promoting apoptosis improve symptoms<sup><a href="#ref-7">7</a></sup>. The ratio between T regulatory cells and T helper 17 (Th-17) cells was found to be reduced in PG lesions but not in sweet syndrome (which is associated with a milder skin inflammation). T regulatory cells are involved in preventing auto-inflammation and therefore an impairment in the level of these cells may allow the uncontrolled activation of other pro-inflammatory cells and cytokines, such as Th-17 and IL-17<sup><a href="#ref-21">21</a></sup>. In addition, T-cell clonal expansions have been seen in patients with PG early in the disease course<sup><a href="#ref-6">6</a></sup>. Histologically, the cigarette paper appearance of PG scars was not consistent with a thinning of the dermis, but rather significantly fewer T helper cells and fibroblasts<sup><a href="#ref-20">20</a></sup>.</p><p class="" id=d14105e498>The relationship between external triggers (that is, pathergy) and genetic factors is poorly understood<sup><a href="#ref-5">5</a></sup>. Pathergy has been suggested to be caused by increased activity of polymorphonuclear cells because of the presence of neutrophils in pathergic lesions of Behet disease<sup><a href="#ref-7">7</a></sup>. However, further research is needed to confirm this theory in PG.</p><p class="" id=d14105e509>Wang <i>et al</i>.<sup><a href="#ref-20">20</a></sup> (2017) hypothesized that abnormal cytokine expression and an adaptive immune response targeted at pilosebaceous units are responsible for the development of PG. In contrast with psoriasis and venous stasis, ulcerations in PG never occurred at sites of previous ulcers; biopsies of healed and non-lesional skin resulted in ulceration (pathergy) only in the latter. Wang <i>et al</i>. hypothesize that this is due to the loss of an autoantigen target, specifically follicular adnexal structures. To further this theory, PG ulcerations (unlike sweet syndrome, scleroderma, and other autoimmune disorders) do not occur in areas lacking follicular adnexal structures, such as the nipple-areolar complex, palmar surface of the hand, and plantar surface of the foot<sup><a href="#ref-20">20</a></sup>. Again, future studies are required to test this hypothesis.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e530>Clinical presentation and comorbidities</h2><p class="" id=d14105e533>There are multiple subtypes of PG, including ulcerative, bullous, pustular, vegetative, and peristomal and post-surgical PG, the latter two being the most commonly pathergic variants. Ulcerative (classic) PG is the most common subtype and usually is seen on the legs. Subtypes can vary in aggression and are associated with different systemic diseases (<a href="#T2">Table 2</a>). The majority of individuals have one to three lesions, and lesions typically cover less than 5% of the total body surface area. Lesions heal with a cigarette paperlike or cribriform scar, and epithelium from the borders extends into the ulcer (referred to as Gullivers sign)<sup><a href="#ref-4">4</a>,<a href="#ref-6">6</a></sup>. Given the association between PG and IBD, RA, and hematologic conditions, other extra-cutaneous manifestations may also be present. This includes ocular (scleritis and ulceration), pulmonary (aseptic nodules), splenic, and musculoskeletal (sterile polyarthritis and neutrophilic myositis) involvement<sup><a href="#ref-4">4</a></sup>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Different clinical presentations of pyoderma gangrenosum and their associated systemic diseases<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a>,<a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below id=T2-no-row-shading><a name=T2-no-row-shading class=n-a></a><thead><a name=d14105e576 class=n-a></a><tr><a name=d14105e578 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e580 class=n-a></a>Variant of pyoderma<br class=br>gangrenosum</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e585 class=n-a></a>Common location</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e588 class=n-a></a>Presentation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e591 class=n-a></a>Associated disease</th></tr></thead><tbody><a name=d14105e596 class=n-a></a><tr><a name=d14105e598 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e600 class=n-a></a>Ulcerative (classic)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e603 class=n-a></a>Lower extremities</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e606 class=n-a></a>Rapid progression<br class=br>Violaceous undermined border<br class=br>Very painful</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e613 class=n-a></a>Inflammatory bowel disease (IBD)<br class=br>Arthritis<br class=br>Myeloproliferative disease</td></tr><tr><a name=d14105e621 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e623 class=n-a></a>Bullous</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e626 class=n-a></a>Face</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e629 class=n-a></a>Superficial bulla<br class=br>Blue-gray border</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e634 class=n-a></a>Myeloproliferative disease (that is, acute<br class=br>myeloid leukemia)</td></tr><tr><a name=d14105e640 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e642 class=n-a></a>Pustular</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e645 class=n-a></a>Legs<br class=br>Upper trunk</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e650 class=n-a></a>Painful pustules<br class=br>Red halo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e655 class=n-a></a>IBD</td></tr><tr><a name=d14105e659 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e661 class=n-a></a>Vegetative</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e664 class=n-a></a>Trunk</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e667 class=n-a></a>Superficial ulcer<br class=br>No violaceous border</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e672 class=n-a></a>None</td></tr><tr><a name=d14105e676 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e678 class=n-a></a>Peristomal</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e681 class=n-a></a>Near stoma site</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e684 class=n-a></a>Painful ulcer<br class=br>Violaceous undermined border</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e689 class=n-a></a>IBD<br class=br>Enteric malignancies</td></tr><tr><a name=d14105e696 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e698 class=n-a></a>Post-surgical (procedural)<br class=br>(after nipple piercing)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e703 class=n-a></a>Surgery site (breast,<br class=br>abdomen most common)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e708 class=n-a></a>Rapid progression<br class=br>Active and undermined border<br class=br>Pain out of proportion to lesion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e715 class=n-a></a>Fewer cases of underlying systemic disease<br class=br>(compared with classic form)<sup><a href="#ref-23">23</a></sup></td></tr><tr><a name=d14105e724 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e726 class=n-a></a>Pyostomatitis vegetans</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e729 class=n-a></a>Buccal gingiva, labial and<br class=br>buccal mucosa</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e734 class=n-a></a>Multiple small white or yellow pustules<br class=br>Erythema<br class=br>Edema</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e741 class=n-a></a>IBD</td></tr></tbody></table></div><p class="" id=d14105e748>The average time between surgery and the first symptoms of postoperative PG was 11 days. More invasive procedures and patients with chronic disease have a higher risk of developing this subtype. In one retrospective analysis, about 15% of individuals had post-surgical recurrence or exacerbation of existing lesions<sup><a href="#ref-24">24</a></sup>. PG was often diagnosed as a wound infection at first, leading to debridement and ultimately worsening the lesion because of pathergy. Earlier diagnosis and recognition may help prevent morbidity and lessen health-care costs<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d14105e759>In 2018, a large retrospective review was completed by Ashchyan <i>et al</i>., who found that the majority of individuals with PG in the literature were middle-aged white women with an average age at presentation of 51.6 years<sup><a href="#ref-25">25</a></sup>. Ulcers were most common on the lower extremities but may also be seen surrounding stomas, in individuals with IBD (peristomal), on the trunk, upper extremities, head or neck, or other locations<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. Pathergy was seen in about one third of individuals, was more common over the age of 65, and may be underestimated (if no trauma occurred)<sup><a href="#ref-25">25</a>,<a href="#ref-27">27</a></sup>.</p><p class="" id=d14105e784>Two thirds of individuals have an associated comorbidity and IBD is most common (occurring in 0.5% of patients with IBD), especially in individuals under 65<sup><a href="#ref-9">9</a>,<a href="#ref-25">25</a></sup>. In individuals with IBD and concomitant PG, IBD is diagnosed at a younger age, and they are more likely to have a family history of UC, be of black African origin, have a stoma, and be on immunosuppressive medications. The mean time between diagnosis of IBD and PG was about 6 years, and PG occasionally preceded the diagnosis of IBD<sup><a href="#ref-28">28</a></sup>.</p><p class="" id=d14105e798>Other associated comorbidities include arthritis, malignancy (acute and chronic myeloid leukemia [AML and CML] and non-Hodgkin lymphoma), hematologic disorders (myelodysplastic syndrome, polycythemia vera, IgA monoclonal gammopathy of unknown significance [MGUS], and myelofibrosis), arthritis, hidradenitis suppurativa, and depression<sup><a href="#ref-9">9</a>,<a href="#ref-25">25</a>,<a href="#ref-27">27</a></sup>. Hematologic disorders are more common in individuals over 65 years of age<sup><a href="#ref-25">25</a></sup>. Three phenotypes of arthritis are seen in association with PG: RA, bowel-associated arthropathy, and progressive erosive seronegative arthritis. PG (bullous PG in particular) can be the initial presentation of leukemia (most commonly AML) and is a poor prognostic sign<sup><a href="#ref-9">9</a></sup>. One study found that the mortality rate in patients with leukemia and PG was higher than in patients with non-leukemia hematologic malignancies, but further studies are needed to investigate this relationship<sup><a href="#ref-29">29</a></sup>. The paraneoplastic phenomenon can also occur with atypical presentations of PG (atypical locations and vesiculobullous lesions) and is seen more frequently in patients with underlying hematologic disorders<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d14105e827>Necrotizing neutrophilic dermatosis (NND)specifically, necrotizing PG (NPG)is a more severe form of PG seen in critically ill patients with a previous diagnosis of PG. NPG is most commonly associated with hematologic disorders and malignant neoplasms. These patients often mimic necrotizing fasciitis, sepsis, or septic shock given their level of systemic inflammation. Common features of NND include erythematous and necrotizing violaceous margins, ulcerations, pathergy, elevated inflammatory markers, and neutrophil invasion. Tissue biopsy and cultures are critical in distinguishing NPG from necrotizing fasciitis, as NPG does not respond to antibiotics but rather immunosuppressive therapy (that is, steroids)<sup><a href="#ref-30">30</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e837>Diagnosis</h2><p class="" id=d14105e840>Historically, the diagnosis of PG has been challenging given its numerous presentations, clinical similarities with other dermatoses (and other neutrophilic dermatoses), and various associated systemic diseases<sup><a href="#ref-31">31</a></sup>. PG therefore has a high misdiagnosis rate: in a study by Weenig <i>et al</i>., PG was initially diagnosed and treated in 67% of patients before an alternative diagnosis was made<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d14105e854>Given the differences in presentation depending on age, Ashchyan <i>et al</i>.<sup><a href="#ref-25">25</a></sup> have proposed an age-focused initial evaluation for PG: they use a different approach depending on whether the patient is over or under 65 years old. In their study, diagnosis was based on the criteria proposed by Su <i>et al</i>.<sup><a href="#ref-32">32</a></sup> (described in the paragraph and table below),which are centered on PG being a diagnosis of exclusion<sup><a href="#ref-33">33</a></sup>. For patients under 65, the history and physical exam should evaluate for the presence of IBD and the threshold for referral to gastroenterology is lower. For patients over 65, physicians should evaluate for hematologic disorders and malignancy with a possible work-up, including a blood smear, monoclonal gammopathy evaluation, and a lower threshold for referral to hematology for bone marrow studies. They suggest that, regardless of age, all patients receive a skin biopsy with tissue culture, age-appropriate malignancy screening, and complete blood count with differential. Depending on the history and physical, an inflammatory arthritis evaluation, autoimmune work-up, and vasculitis screen may be conducted<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d14105e880>Numerous articles in the literature used the proposed diagnostic criteria for classic ulcerative PG by Su <i>et al</i>.<sup><a href="#ref-34">34</a></sup> (2004). The diagnostic criteria, which are based on PGs being a diagnosis of exclusion, are listed in <a href="#T3">Table 3</a>. Biopsy is pivotal in the exclusion of other etiologies, and the best location for biopsy is the active ulcer border. The investigation of regular histopathology, including special staining and tissue culture, is required. In order for a diagnosis of PG to be made, both one major criterion and two minor criteria need to be present. Diagnostic criteria for the bullous, pustular, and vegetative variants of PG were also proposed<sup><a href="#ref-34">34</a></sup>.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Comparison of the different diagnostic criteria suggested for pyoderma gangrenosum<sup><a href="#ref-31">31</a>,<a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below id=T3-no-row-shading><a name=T3-no-row-shading class=n-a></a><thead><a name=d14105e920 class=n-a></a><tr><a name=d14105e922 class=n-a></a><th align=left colspan=3 rowspan=1 valign=top><a name=d14105e924 class=n-a></a>Proposed diagnostic criteria</th></tr><tr><a name=d14105e928 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e930 class=n-a></a>Su <i>et al</i>.<sup><a href="#ref-34">34</a></sup> criteria</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e940 class=n-a></a>The Delphi Consensus of<br class=br>International Experts</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14105e945 class=n-a></a>PARACELSUS score</th></tr></thead><tbody><a name=d14105e950 class=n-a></a><tr><a name=d14105e952 class=n-a></a><td align=left colspan=3 rowspan=1 valign=top><a name=d14105e954 class=n-a></a><b>Major criteria</b></td></tr><tr><a name=d14105e959 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e961 class=n-a></a>Other ulcerating conditions excluded (that is,<br class=br>biopsy and other investigations)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e966 class=n-a></a>Biopsy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e969 class=n-a></a>Exclude other differential diagnoses</td></tr><tr><a name=d14105e973 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e975 class=n-a></a>Typical clinical presentation of classic<br class=br>pyoderma gangrenosum<sup><a href="#TFN2">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e983 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e985 class=n-a></a>Reddish-violaceous ulcer border</td></tr><tr><a name=d14105e989 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e991 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e993 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e995 class=n-a></a>Progressive ulceration<br class=br>(developed in &lt;6 weeks)</td></tr><tr><a name=d14105e1001 class=n-a></a><td align=left colspan=3 rowspan=1 valign=top><a name=d14105e1003 class=n-a></a><b>Minor criteria<sup><a href="#TFN3">b</a></sup></b></td></tr><tr><a name=d14105e1012 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1014 class=n-a></a>Histopathology findings</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1017 class=n-a></a>Histopathology findings</td><td align=left colspan=1 rowspan=1 style="background-color:#E7E6E6" valign=top><a name=d14105e1020 class=n-a></a>Histopathology findings</td></tr><tr><a name=d14105e1024 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1026 class=n-a></a>Typical systemic diseases present</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1029 class=n-a></a>Typical systemic diseases present</td><td align=left colspan=1 rowspan=1 style="background-color:#E7E6E6" valign=top><a name=d14105e1032 class=n-a></a>Typical systemic diseases present<br class=br>inflammatory bowel disease, inflammatory<br class=br>arthritis</td></tr><tr><a name=d14105e1040 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1042 class=n-a></a>Treatment responsive to systemic steroids</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1045 class=n-a></a>Treatment responsive to<br class=br>immunosuppressants</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1050 class=n-a></a>Improvement in symptoms by<br class=br>immunosuppressants</td></tr><tr><a name=d14105e1056 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1058 class=n-a></a>History of pathergy and cribiform scarring</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1061 class=n-a></a>Pathergy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1064 class=n-a></a>Pathergy</td></tr><tr><a name=d14105e1068 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1070 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1072 class=n-a></a>Cribiform scarring</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1075 class=n-a></a></td></tr><tr><a name=d14105e1078 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1080 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1082 class=n-a></a>Pain, undermined border, peripheral<br class=br>erythema</td><td align=left colspan=1 rowspan=1 style="background-color:#E7E6E6" valign=top><a name=d14105e1087 class=n-a></a>Undermined border</td></tr><tr><a name=d14105e1092 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1094 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1096 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1098 class=n-a></a>Pain</td></tr><tr><a name=d14105e1102 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1104 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1106 class=n-a></a>Papule, pustule, or vesicle that<br class=br>ulcerated</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1111 class=n-a></a>Irregular ulcer shape</td></tr><tr><a name=d14105e1115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1117 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1119 class=n-a></a>Multiple ulcerations (at least one on<br class=br>lower leg)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14105e1124 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d14105e1131 class=n-a></a><p id=TFN2> <sup>a</sup>Progressive (1 to 2 cm/day or increase by 50% in 1 month), painful, irregular and undermined border, violaceous color, preceded by papule, pustule, or bulla.</p><p id=TFN3><sup>b</sup>For the PARACELSUS score, minor criteria have a white background and additional criteria have a gray background.</p></div></div></div><p class="" id=d14105e1147>Given the difficulty in diagnosing PG and excluding other diagnoses, 12 physicians collaborated to create a diagnostic criterion for classic ulcerative PG. The Delphi Consensus of International Experts diagnostic criteria are composed of one major and eight minor criteria (<a href="#T3">Table 3</a>). In order for the diagnosis to be made, one major and four minor criteria must be present<sup><a href="#ref-31">31</a></sup>. Consensus was not reached regarding the inclusion of hematologic disease as a minor criterion (unlike IBD and inflammatory arthritis). Given the prevalence of hematologic disease in PG, future iterations should consider its addition as a minor criterion. In addition, the use of biopsy as a major criterion may not reflect actual clinical practice<sup><a href="#ref-33">33</a></sup>. Interestingly, one study found that only 12% of individuals had histological evidence of a neutrophilic infiltrate and that less than 10% had a biopsy consistent with PG<sup><a href="#ref-27">27</a></sup>.</p><p class="" id=d14105e1165>Around the same time as the development of the Delphi criteria above, Jockenhfer <i>et al</i>.<sup><a href="#ref-35">35</a></sup> developed the PARACELSUS score as a separate diagnostic tool for PG. This score was developed on the basis of a review of the literature. The criteria are listed in <a href="#T3">Table 3</a>. Major criteria (assigned 3 points) were present in more than 95% of individuals, minor criteria (2 points) were present in 61 to 95%, and additional criteria (1 point) were present in not more than 60%. It is worth noting that these criteria were applied to only 60 individuals with lower-extremity PG and 50 patients with venous leg ulcers (control group) and did not consider other locations or ulcerative conditions. Individuals with PG all had a score of more than 10, whereas patients with venous ulcers all had scores of less than 7<sup><a href="#ref-35">35</a></sup>. All three criteria are compared in <a href="#T3">Table 3</a>, and similar criteria are grouped together.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e1188>Treatment</h2><p class="" id=d14105e1191>PG is a challenging condition to manage, and treatment focuses on reducing systemic inflammation. There is a lack of large randomized controlled trials (RCTs) in the literature and therefore the majority of treatment decisions are based on expert opinion, case reports and case series, and small cohort studies. Treatment decisions are personalized to reflect the location, number, and size of lesion(s), extra-cutaneous involvement, underlying systemic disease, side effect profiles, cost, and patient preference<sup><a href="#ref-4">4</a></sup>.</p><div class=section><a name=d14105e1198 class=n-a></a><h3 class=section-title>Topical and intralesional therapy</h3><p class="" id=d14105e1203>The best evidence in the literature regarding topical therapy is for corticosteroids and tacrolimus. A case series conducted in 2011 found topical therapy to be used most often in peristomal PG, smaller lesions, and localized PG (&lt;5% body surface area, &lt;3 lesions, and lesions &lt;2 cm<sup>2</sup>)<sup><a href="#ref-5">5</a>,<a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. One review found that topical tacrolimus 0.3% promoted lesion resolution in mild and localized PG<sup><a href="#ref-37">37</a></sup>. Intralesional steroids, applied to the active border of the lesion surrounding the ulcerated area, can also be used in small and localized PG<sup><a href="#ref-4">4</a></sup>. However, there is little information on which steroid class to use, the frequency of application, the dosage of tacrolimus to use, and the best dressing to apply afterwards<sup><a href="#ref-36">36</a></sup>. Other topical therapies include sodium cromoglycate, nicotine, dapsone, and 5-aminosalicylic acid (5-ASA)<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d14105e1236>Topical therapy was often used alongside other systemic therapies (for example, prednisone), and ulcer size was an important predictive factor in lesion resolution. A prospective cohort study found that less than 50% of individuals had healed (no longer required dressings) with topical therapy alone in a 6-month period and that one third of individuals required systemic therapy<sup><a href="#ref-38">38</a></sup>. However, improvements were slow and relapses were not uncommon. Therefore, topical therapy can be used concomitantly with systemic therapy or in patients who are resistant to or cannot tolerate steroids<sup><a href="#ref-37">37</a></sup>.</p></div><div class=section><a name=d14105e1248 class=n-a></a><h3 class=section-title>Systemic therapy</h3><p class="" id=d14105e1253>Monotherapy can be used in patients with mild PG. Examples of typical monotherapy agents include steroids, tacrolimus, topical sodium cromoglycate, nicotine, 5-ASA, intralesional triamcinolone, and intralesional cyclosporine. Current research is targeted at the development of new biologic agents that target different inflammatory cytokines and signaling pathways<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d14105e1260>The most commonly used first-line treatment in the management of PG is systemic steroids<sup><a href="#ref-4">4</a>,<a href="#ref-27">27</a>,<a href="#ref-39">39</a></sup>. An RCT comparing oral cyclosporin (4 mg/kg per day) with prednisolone (0.75 mg/kg per day) found no difference between these medications in lesion-healing speed (in a 6-week period), treatment response, resolution of wounds, pain, quality of life, treatment failure, and recurrence. Overall, about half of all PG ulcers had healed by 6 months. Therefore, treatment is guided by the side effect profiles of these two medications (serious infections in steroids and hypertension and renal dysfunction in the ciclosporin group)<sup><a href="#ref-39">39</a></sup>.</p><p class="" id=d14105e1277>Other systemic therapies (cyclophosphamide, methotrexate, mycophenolate mofetil, sulfasalazine, and azathioprine) have been used in the literature, but more data are needed to evaluate their efficacy in treating PG<sup><a href="#ref-4">4</a></sup>. The addition of topical or systemic antibiotics or anti-neutrophilic agents (dapsone and colchicine) has traditionally been based on the providers preference. The benefits of using anti-neutrophilic agents are for both their anti-inflammatory effects and prophylaxis against <i>Pneumocystis jiroveci</i><sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d14105e1290>Combination therapy is often used in the treatment of PG<sup><a href="#ref-27">27</a></sup>. There are few studies comparing different combination therapies in the literature. In two observational studies,100% of in-patients achieved either partial or complete healing when given combination therapy with systemic steroids and another immunomodulator (ciclosporin, dapsone, clofazimine, and cyclophosphamide)<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>. Currently, the use of well-studied combinations of immunomodulators (for example, cyclosporine/tacrolimus, mycophenolate mofetil, and prednisone) is also recommended in PG<sup><a href="#ref-6">6</a></sup>.</p></div><div class=section><a name=d14105e1309 class=n-a></a><h3 class=section-title>Biologics</h3><p class="" id=d14105e1314>Multiple different biologics have been proposed for the treatment of PG. Agents targeting TNF are the best studied, given their ability to treat coexisting IBD (other than etanercept)<sup><a href="#ref-4">4</a></sup>. Steroids appear to be less efficacious in treating PG with comorbid IBD when compared with biologics<sup><a href="#ref-42">42</a></sup>. However, the use of biologics is not without potential harm. Rare adverse effects of biologics include lymphoma, congestive heart failure, multiple sclerosis, peripheral neuropathy, and anti-DNA antibody formation. Reactivation of tuberculosis has been seen in the use of anti-TNF therapy<sup><a href="#ref-6">6</a></sup>. Patients should be made aware of the risks of therapy before beginning treatment.</p><p class="" id=d14105e1329><b><i>Tumor necrosis factor antagonists.</i></b> No TNF antagonist has been proven to be more efficacious than others in the treatment of PG. Their use has been associated with a decrease in C-reactive protein (CRP), IL-1, IL-6, and immune cell adhesion markers<sup><a href="#ref-8">8</a></sup>.</p><p class="" id=d14105e1339>Infliximab, the only biologic to have an associated RCT, functions by restoring the ability of T regulatory cells to inhibit aberrant cytokine production<sup><a href="#ref-4">4</a></sup>. Given this RCT and its rapid onset of effect, infliximab is often preferred in a clinical setting. Thirty patients were randomly assigned to receive either an infusion of infliximab (5 mg/kg) or placebo at week 0 and were reassessed 2 weeks later. If there was no improvement by week 2, everyone was offered open-labelled infliximab at the same dose; 46% of individuals showed clinical improvement with infliximab (compared with 6% with placebo) by 2 weeks, and 69% had improved by week 6 (21% complete resolution). Individuals with lesions of less than 12 weeks duration had a higher improvement/remission rate than those with a longer duration<sup><a href="#ref-43">43</a></sup>.</p><p class="" id=d14105e1350>Adalimumab is a humanized IgG1 monoclonal antibody with activity against TNF. The literature surrounding adalimumab is composed of case reports and small case series; in some of these, it was added to or replaced current therapy because of treatment failure. The majority of the literature showed either complete resolution or partial improvement<sup><a href="#ref-8">8</a></sup>. However, the sample size was small and evidence is limited<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d14105e1362>Etanercept functions as a decoy receptor for TNF and has activity against TNF. Data are limited to case reports and small case series, the majority of which showed clinical improvement or complete resolution<sup><a href="#ref-8">8</a></sup>. However, etanercept is less efficacious than other TNF antagonists in the treatment of coexisting IBD<sup><a href="#ref-4">4</a>,<a href="#ref-6">6</a></sup>.</p><p class="" id=d14105e1376>Golimumab, a newer TNF inhibitor, led to complete ulcer resolution in 24 weeks in a patient who had failed infliximab and adalimumab. Another novel TNF inhibitor is certolizumab pegol. Future studies are needed to further evaluate the use of Golimumab and Certrolizumab Pegol PG<sup><a href="#ref-8">8</a>,<a href="#ref-44">44</a></sup>.</p><p class="" id=d14105e1386><b><i>IL-12 and IL-23 antagonists.</i></b> Ustekinumab blocks the common p40 subunit of IL-12 and IL-23. These two cytokines are important in neutrophil recruitment through their interaction with Th1 and Th17 cells, respectively. Case reports in the literature demonstrate either partial or complete resolution of PG lesions with ustekinumab; however, more studies are needed to confirm efficacy<sup><a href="#ref-6">6</a>,<a href="#ref-8">8</a></sup>.</p><p class="" id=d14105e1399>Tildrakizumab and guselkumab are IL-23 antagonists without simultaneous IL-12 antagonism. Future research is needed to assess their efficacy<sup><a href="#ref-8">8</a></sup>.</p><p class="" id=d14105e1406><b><i>IL-1 antagonists.</i></b> As mentioned above, some PG-associated genetic syndromes are associated with a mutation in the <i>PSTPIP1</i> gene, leading to increased IL-1 production. IL-1 inhibitors, therefore, have the potential of blocking the downstream effects of this mutation, but the evidence is still limited<sup><a href="#ref-4">4</a>,<a href="#ref-8">8</a></sup>.</p><p class="" id=d14105e1422>Anakinra is a competitive inhibitor of IL-1 (both subtypes) with a short half-life (4 to 6 hours). Although the majority of case reports demonstrated partial or complete resolution of ulcers, large daily doses were needed<sup><a href="#ref-8">8</a></sup>. In comparison with other biologics, anakinra may be less effective in its management of PG<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d14105e1434>Canakinumab is a monoclonal antibody targeted against IL-1 with a longer half-life (about 1 month)<sup><a href="#ref-8">8</a></sup>. Five patients with PG (without systemic disease) who had all failed steroids were given canakinumab. Four of the five individuals had clinical improvement in 16 weeks, and three individuals had complete resolution of their lesions in this time period. However, one patient in this study had new-onset rapidly progressive genital ulcers, likely representing PG at a different location<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d14105e1445>Gevokizumab, another monoclonal antibody targeting IL-1, showed promise in the treatment of PG; however, the rights to this drug were sold in 2016<sup><a href="#ref-8">8</a></sup>.</p><p class="" id=d14105e1452><b><i>IL-6 antagonists.</i></b> Tocilizumab has been successful in treating PG in a patient with RA and interstitial lung disease (ILD), as ILD is a contraindication to TNF inhibitors<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d14105e1462><b><i>JAK/STAT inhibitors.</i></b> Tofacitinib is an oral JAK 1 and 3 inhibitor that is currently approved for use in RA and ulcerative colitis. Three patients with treatment-resistant PG and both comorbid Crohns disease and inflammatory arthritis were given tofacitinib, leading to complete resolution in two patients and symptom improvement in the third by 12 weeks<sup><a href="#ref-45">45</a></sup>.</p><p class="" id=d14105e1472>Ruxolitinib, a JAK-2 inhibitor, was used in a case report of a 64-year-old female with polycythemia vera and bilateral lower-leg PG who had failed multiple immunosuppressive regimens, intravenous immunoglobulin (IVIG), and anakinra. Dramatic healing of the PG lesions was seen within 10 weeks, and complete healing of her lesions was seen after 4 years<sup><a href="#ref-46">46</a></sup>.</p><p class="" id=d14105e1479><b><i>Intravenous immunoglobulin therapy.</i></b> IVIG has been used as an adjunctive strategy for treatment-refractive PG, most commonly as a combination therapy with systemic steroids. One study found that patients with solitary PG lesions are more responsive to IVIG than those with two or more lesions whereas factors such as ulcer location had no meaningful significance<sup><a href="#ref-47">47</a></sup>. The majority of patients showed clinical improvement, and 53% of these individuals had complete resolution. The most common side effects were headache and nausea. However, patients in this study were older and more likely to have comorbidities than other patients in the literature<sup><a href="#ref-48">48</a></sup>. The anti-inflammatory activity of IVIG is likely the reason for lesion resolution<sup><a href="#ref-49">49</a></sup>.</p><p class="" id=d14105e1498><b><i>Phosphodiesterase 4 inhibitors.</i></b> Phosphodiesterase 4 (PDE4) is an enzyme produced by immune cells, and inhibition helps modulate different pro-inflammatory signaling cascades. Apremilast, an oral PDE4 inhibitor, inhibits multiple cytokines involved in these signaling cascades<sup><a href="#ref-8">8</a></sup>. In the literature, there is one case report of resistant vegetative PG with underlying IgA MGUS. Complete healing of one lesion and partial healing of another were seen when apremilast was used concomitantly with oral prednisone<sup><a href="#ref-50">50</a></sup>. Further studies are needed to better characterize this treatment.</p></div><div class=section><a name=d14105e1514 class=n-a></a><h3 class=section-title>Wound care</h3><p class="" id=d14105e1519>Treatment of PG is multifaceted and is not limited to pharmacotherapy. Other aspects of treatment include lifestyle modification (smoking cessation, nutrition, exercise, and prevention of hyperglycemia), the avoidance of triggers and trauma (given the high prevalence of pathergy), wound care, analgesia, prevention of superimposed infection, and compression therapy (to minimize edema)<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d14105e1526>Gentle cleaning of the wound, proper use of topical antimicrobial agents (in the setting of critical colonization) if indicated, a moist wound environment, and control of edema are essential in the management of PG. Multiple dressings have been used in the literature for the treatment of PG. Dressing choice depends on the ulcers characteristics (drainage, size, location, and so on). Sharp debridement should be avoided in PG given the high rate of pathergy but may be needed depending on the amount of non-viable tissue<sup><a href="#ref-5">5</a></sup>. However, about 30% of individuals have undergone debridement by a wound care specialist because of diagnostic uncertainty<sup><a href="#ref-26">26</a></sup>. Other wound management modalities include negative pressure wound therapy and hyperbaric oxygen, both of which show promise<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d14105e1541>Compression therapy is used as an adjunct to immunosuppression in the management of PG as it is paramount in reducing any associated edema and promoting wound healing. One report commented on the importance of multimodal therapy and specifically compression therapy, given the lack of wound healing likely due to prednisone-induced edema<sup><a href="#ref-51">51</a></sup>.</p></div><div class=section><a name=d14105e1549 class=n-a></a><h3 class=section-title>Analgesia and multidisciplinary management</h3><p class="" id=d14105e1554>Pain control is an important tenet in the management of PG and often involves the use of non-steroidal anti-inflammatory drugs and opioids. Neuropathic medications can also be used if nerve damage is present<sup><a href="#ref-5">5</a></sup>. Opioids may be associated with decreased healing in venous ulcers (in addition to their other adverse effects) and therefore alternative strategies for analgesia should be considered first<sup><a href="#ref-52">52</a></sup>.</p><p class="" id=d14105e1565>Given the association between PG and underlying systemic disease, referrals to appropriate subspecialties (that is, gastroenterology, rheumatology, hematology, and so on) are required. In addition, mental health support is warranted given the association between PG and major depressive disorder<sup><a href="#ref-27">27</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e1577>Conclusions</h2><p class="" id=d14105e1580>PG is a rare neutrophilic dermatosis with a complex pathophysiology and difficult diagnosis. It is important to note that owing to the rarity of this condition, there are very few RCTs. The majority of other publications are cohort studies, case reports, and case studies, many of which have a small sample size. However, current research has been promising and continues to provide new potential targets for therapy. Recently, multiple diagnostic criteria have been proposed to improve the accuracy of diagnosis. Although the pathophysiology of PG is still incompletely understood, the discovery of new inflammatory cytokines and signal cascades has led to the development of novel biologic therapy. Long-term data on the use of immunosuppressive medications, biologics, and small-molecule therapy are lacking. Moreover, it is difficult to assess long-term efficacy, adverse events, and remission rates as outcome measures for PG are not widely available. Additional studies are needed to better characterize these medications and subsequently to compare available treatments.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14105e1586>Ethics</h2><p class="" id=d14105e1589>Written informed consent was obtained from the patient in <a href="#f1">Figure 1</a> for the use and publication of this image.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d14105e1599 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d14486>References</h2><div class="section ref-list"><a name=d14105e1599 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d14105e1606 class=n-a></a>Langan SM, Groves RW, Card TR, <i> et al.</i>: Incidence, Mortality, and Disease Associations of Pyoderma Gangrenosum in the United Kingdom: A Retrospective Cohort Study. <i>J Invest Dermatol.</i> 2012. <b>132</b>(9): 216670. <a target=xrefwindow id=d14105e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/22534879">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1620 href="https://doi.org/10.1038/jid.2012.130">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736395111"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e1629 class=n-a></a>Xu A, Balgobind A, Strunk A, <i> et al.</i>: Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis. <i>J Am Acad Dermatol.</i> 2019. pii: S0190-9622(19)32494-6. <a target=xrefwindow id=d14105e1637 href="http://www.ncbi.nlm.nih.gov/pubmed/31400451">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1640 href="https://doi.org/10.1016/j.jaad.2019.08.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736395111">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d14105e1653 class=n-a></a>Cohen PR: Neutrophilic Dermatoses: a review of current treatment options. <i>Am J Clin Dermatol.</i> 2009; <b>10</b>(5): 30112. <a target=xrefwindow id=d14105e1661 href="http://www.ncbi.nlm.nih.gov/pubmed/19658442">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1664 href="https://doi.org/10.2165/11310730-000000000-00000">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d14105e1673 class=n-a></a>Alavi A, French LE, Davis MD, <i> et al.</i>: Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. <i>Am J Clin Dermatol.</i> 2017; <b>18</b>(3): 355372. <a target=xrefwindow id=d14105e1684 href="http://www.ncbi.nlm.nih.gov/pubmed/28224502">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1687 href="https://doi.org/10.1007/s40257-017-0251-7">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d14105e1696 class=n-a></a>McKenzie F, Arthur M, Ortega-Loayza AG: Pyoderma Gangrenosum: What Do We Know Now? <i>Curr Derm Rep.</i> 2018; <b>7</b>: 147157. <a target=xrefwindow id=d14105e1704 href="https://doi.org/10.1007/s13671-018-0224-y">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d14105e1714 class=n-a></a>Patel F, Fitzmaurice S, Duong C, <i> et al.</i>: Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. <i>Acta Derm Venerol.</i> 2015; <b>95</b>(5): 52531. <a target=xrefwindow id=d14105e1725 href="http://www.ncbi.nlm.nih.gov/pubmed/25387526">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1728 href="https://doi.org/10.2340/00015555-2008">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d14105e1737 class=n-a></a>Braswell SF, Kostopoulos TC, Ortega-Loayza AG: Pathophysiology of pyoderma gangrenosum (PG): an updated review. <i>J Am Acad Dermatol.</i> 2015; <b>73</b>(4): 6918. <a target=xrefwindow id=d14105e1745 href="http://www.ncbi.nlm.nih.gov/pubmed/26253362">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1748 href="https://doi.org/10.1016/j.jaad.2015.06.021">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d14105e1757 class=n-a></a>McKenzie F, Cash D, Gupta A: Biologic and small-molecule medications in the management of pyoderma gangrenosum. <i>J Dermatolog Treat.</i> 2019; <b>30</b>(3): 264276. <a target=xrefwindow id=d14105e1765 href="http://www.ncbi.nlm.nih.gov/pubmed/30051737">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1768 href="https://doi.org/10.1080/09546634.2018.1506083">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d14105e1777 class=n-a></a>DeFilippis EM, Feldman SR, Huang WW: The genetics of pyoderma gangrenosum and implications for treatment: A systematic review. <i>Br J Dermatol.</i> 2015; <b>172</b>(6): 14871497. <a target=xrefwindow id=d14105e1785 href="http://www.ncbi.nlm.nih.gov/pubmed/25350484">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1788 href="https://doi.org/10.1111/bjd.13493">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d14105e1797 class=n-a></a>Khandpur S, Mehta S, Reddy BS: Pyoderma gangrenosum in two siblings: a familial predisposition. <i>Pediatr Dermatol.</i> 2001; <b>18</b>(4): 30812. <a target=xrefwindow id=d14105e1805 href="http://www.ncbi.nlm.nih.gov/pubmed/11576404">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1808 href="https://doi.org/10.1046/j.1525-1470.2001.01936.x">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d14105e1817 class=n-a></a>Boussofara L, Gammoudi R, Ghariani N: Familial pyoderma gangrenosum in association with common variable immunodeficiency. <i>Br J Dermatol.</i> 2013; <b>169</b>(4): 9446. <a target=xrefwindow id=d14105e1825 href="http://www.ncbi.nlm.nih.gov/pubmed/23662950">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1828 href="https://doi.org/10.1111/bjd.12431">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d14105e1838 class=n-a></a>al-Rimawi HS, Abuekteish FM, Daoud AS, <i> et al.</i>: Familial pyoderma gangrenosum presenting in infancy. <i>Eur J Pediatr.</i> 1996; <b>155</b>(9): 75962. <a target=xrefwindow id=d14105e1849 href="http://www.ncbi.nlm.nih.gov/pubmed/8874107">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1852 href="https://doi.org/10.1007/bf02002902">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d14105e1861 class=n-a></a>Shands JW Jr, Flowers FP, Hill HM, <i> et al.</i>: Pyoderma gangrenosum in a kindred. Precipitation by surgery or mild physical trauma. <i>J Am Acad Dermatol.</i> 1987; <b>16</b>(5 Pt 1): 9314. <a target=xrefwindow id=d14105e1872 href="http://www.ncbi.nlm.nih.gov/pubmed/3584575">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1875 href="https://doi.org/10.1016/S0190-9622(87)70116-9">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736770618"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e1884 class=n-a></a>Maggio MC, Ceccherini I, Grossi A, <i> et al.</i>: PAPA and FMF in two siblings: Possible amplification of clinical presentation? A case report. <i>Ital J Pediatr.</i> 2019; <b>45</b>(1): 111. <a target=xrefwindow id=d14105e1895 href="http://www.ncbi.nlm.nih.gov/pubmed/31443670">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1898 href="https://doi.org/10.1186/s13052-019-0705-z">Publisher Full Text </a> | <a target=xrefwindow id=d14105e1902 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6708240">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736770618">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727836131"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e1915 class=n-a></a>Ortega-Loayza AG, Nugent WH, Lucero OM, <i> et al.</i>: Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. <i>Br J Dermatol.</i> 2018; <b>178</b>(1): e35e36. <a target=xrefwindow id=d14105e1926 href="http://www.ncbi.nlm.nih.gov/pubmed/28734003">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1929 href="https://doi.org/10.1111/bjd.15837">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727836131">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d14105e1942 class=n-a></a>Alves de Medeiros AK, Speeckaert R, Desmet E, <i> et al.</i>: JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. <i>PLoS One.</i> 2016; <b>11</b>(10): e0164080. <a target=xrefwindow id=d14105e1953 href="http://www.ncbi.nlm.nih.gov/pubmed/27711196">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1956 href="https://doi.org/10.1371/journal.pone.0164080">Publisher Full Text </a> | <a target=xrefwindow id=d14105e1960 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5053514">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d14105e1969 class=n-a></a>Marzano AV, Fanoni D, Antiga E, <i> et al.</i>: Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. <i>Clin Exp Immunol.</i> 2014; <b>178</b>(1): 4856. <a target=xrefwindow id=d14105e1980 href="http://www.ncbi.nlm.nih.gov/pubmed/24903614">PubMed Abstract </a> | <a target=xrefwindow id=d14105e1983 href="https://doi.org/10.1111/cei.12394">Publisher Full Text </a> | <a target=xrefwindow id=d14105e1987 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4360193">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727097051"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e1997 class=n-a></a>Marzano AV, Damiani G, Ceccherini I, <i> et al.</i>: Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). <i>Br J Dermatol.</i> 2017; <b>176</b>(6): 15881598. <a target=xrefwindow id=d14105e2008 href="http://www.ncbi.nlm.nih.gov/pubmed/27943240">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2011 href="https://doi.org/10.1111/bjd.15226">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727097051">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d14105e2024 class=n-a></a>Kolios AG, Maul JT, Meier B, <i> et al.</i>: Canakinumab in adults with steroid-refractory pyoderma gangrenosum. <i>Br J Dermatol.</i> 2015; <b>173</b>(5): 121623. <a target=xrefwindow id=d14105e2035 href="http://www.ncbi.nlm.nih.gov/pubmed/26471257">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2038 href="https://doi.org/10.1111/bjd.14037">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732583693"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2047 class=n-a></a>Wang EA, Steel A, Luxardi G, <i> et al.</i>: Classic Ulcerative Pyoderma Gangrenosum Is a T Cell-Mediated Disease Targeting Follicular Adnexal Structures: A Hypothesis Based on Molecular and Clinicopathologic Studies. <i>Front Immunol.</i> 2018; <b>8</b>: 1980. <a target=xrefwindow id=d14105e2058 href="http://www.ncbi.nlm.nih.gov/pubmed/29379508">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2061 href="https://doi.org/10.3389/fimmu.2017.01980">Publisher Full Text </a> | <a target=xrefwindow id=d14105e2065 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5775228">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732583693">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d14105e2078 class=n-a></a>Caproni M, Antiga E, Volpi W, <i> et al.</i>: The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. <i>Br J Dermatol.</i> 2015; <b>173</b>(1): 2758. <a target=xrefwindow id=d14105e2089 href="http://www.ncbi.nlm.nih.gov/pubmed/25601218">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2092 href="https://doi.org/10.1111/bjd.13670">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d14105e2101 class=n-a></a>Tolkachjov SN, Fahy AS, Wetter DA, <i> et al.</i>: Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. <i>J Am Acad Dermatol.</i> 2015; <b>73</b>(4): 61522. <a target=xrefwindow id=d14105e2112 href="http://www.ncbi.nlm.nih.gov/pubmed/26209218">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2115 href="https://doi.org/10.1016/j.jaad.2015.06.054">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d14105e2124 class=n-a></a>Mejia LM: Oral Manifestations of Gastrointestinal Disorders. <i>Atlas Oral Maxillofac Surg Clin North Am.</i> 2017; <b>25</b>(2): 93104. <a target=xrefwindow id=d14105e2132 href="http://www.ncbi.nlm.nih.gov/pubmed/28778312">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2135 href="https://doi.org/10.1016/j.cxom.2017.04.002">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731387026"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2145 class=n-a></a>Xia FD, Liu K, Lockwood S, <i> et al.</i>: Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis. <i>J Am Acad Dermatol.</i> 2018; <b>78</b>(2): 310314.e1. <a target=xrefwindow id=d14105e2156 href="http://www.ncbi.nlm.nih.gov/pubmed/28947285">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2159 href="https://doi.org/10.1016/j.jaad.2017.09.040">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731387026">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732683252"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2172 class=n-a></a>Ashchyan HJ, Butler DC, Nelson CA, <i> et al.</i>: The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. <i>JAMA Dermatol.</i> 2018; <b>154</b>(4): 409413. <a target=xrefwindow id=d14105e2183 href="http://www.ncbi.nlm.nih.gov/pubmed/29450453">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2186 href="https://doi.org/10.1001/jamadermatol.2017.5978">Publisher Full Text </a> | <a target=xrefwindow id=d14105e2190 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5876860">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732683252">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d14105e2203 class=n-a></a>Okhovat JP, Shinkai K: Pyoderma gangrenosum. <i>JAMA Dermatol.</i> 2014; <b>150</b>(9): 1032. <a target=xrefwindow id=d14105e2211 href="http://www.ncbi.nlm.nih.gov/pubmed/25207536">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2214 href="https://doi.org/10.1001/jamadermatol.2014.1307">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d14105e2223 class=n-a></a>Binus AM, Qureshi AA, Li VW, <i> et al.</i>: Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. <i>Br J Dermatol.</i> 2011; <b>165</b>(6): 124450. <a target=xrefwindow id=d14105e2234 href="http://www.ncbi.nlm.nih.gov/pubmed/21824126">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2237 href="https://doi.org/10.1111/j.1365-2133.2011.10565.x">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d14105e2246 class=n-a></a>Farhi D, Cosnes J, Zizi N, <i> et al.</i>: Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. <i>Medicine (Baltimore).</i> 2008; <b>87</b>(5): 28193. <a target=xrefwindow id=d14105e2257 href="http://www.ncbi.nlm.nih.gov/pubmed/18794711">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2260 href="https://doi.org/10.1097/MD.0b013e318187cc9c">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736067335"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2269 class=n-a></a>Gupta AS, Ortega-Loayza AG: Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. <i>Ann Hematol.</i> 2019; <b>98</b>(9): 22472248. <a target=xrefwindow id=d14105e2277 href="http://www.ncbi.nlm.nih.gov/pubmed/31230113">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2280 href="https://doi.org/10.1007/s00277-019-03732-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736067335">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734350529"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2294 class=n-a></a>Sanchez IM, Lowenstein S, Johnson KA, <i> et al.</i>: Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis. <i>JAMA Dermatol.</i> 2019; <b>155</b>(1): 7984. <a target=xrefwindow id=d14105e2305 href="http://www.ncbi.nlm.nih.gov/pubmed/30383110">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2308 href="https://doi.org/10.1001/jamadermatol.2018.3890">Publisher Full Text </a> | <a target=xrefwindow id=d14105e2312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6439570">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734350529">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732683251"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2325 class=n-a></a>Maverakis E, Ma C, Shinkai K, <i> et al.</i>: Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. <i>JAMA Dermatol.</i> 2018; <b>154</b>(4): 461466. <a target=xrefwindow id=d14105e2336 href="http://www.ncbi.nlm.nih.gov/pubmed/29450466">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2339 href="https://doi.org/10.1001/jamadermatol.2017.5980">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732683251">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d14105e2352 class=n-a></a>Weenig RH, Davis MD, Dahl PR, <i> et al.</i>: Skin ulcers misdiagnosed as pyoderma gangrenosum. <i>N Engl J Med.</i> 2002; <b>347</b>(18): 14128. <a target=xrefwindow id=d14105e2363 href="http://www.ncbi.nlm.nih.gov/pubmed/12409543">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2366 href="https://doi.org/10.1056/NEJMoa013383">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736231005"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2375 class=n-a></a>Kaffenberger BH, Trinidad J: Diagnosis uPGrade-Advances in Pyoderma Gangrenosum. <i>JAMA Dermatol.</i> 2018; <b>154</b>(4): 397398. <a target=xrefwindow id=d14105e2383 href="http://www.ncbi.nlm.nih.gov/pubmed/29450448">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2386 href="https://doi.org/10.1001/jamadermatol.2017.5979">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736231005">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d14105e2399 class=n-a></a>Su WP, Davis MD, Weenig RH, <i> et al.</i>: Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. <i>Int J Dermatol.</i> 2004; <b>43</b>(11): 790800. <a target=xrefwindow id=d14105e2410 href="http://www.ncbi.nlm.nih.gov/pubmed/15533059">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2413 href="https://doi.org/10.1111/j.1365-4632.2004.02128.x">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732592498"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2422 class=n-a></a>Jockenhfer F, Wollina U, Salva KA, <i> et al.</i>: The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. <i>Br J Dermatol.</i> 2019; <b>180</b>(3): 615620. <a target=xrefwindow id=d14105e2433 href="http://www.ncbi.nlm.nih.gov/pubmed/29388188">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2436 href="https://doi.org/10.1111/bjd.16401">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732592498">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d14105e2450 class=n-a></a>Le Cleach L, Moguelet P, Perrin P, <i> et al.</i>: Is topical monotherapy effective for localized pyoderma gangrenosum? <i>Arch Dermatol.</i> 2011; <b>147</b>(1): 1013. <a target=xrefwindow id=d14105e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/21242400">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2464 href="https://doi.org/10.1001/archdermatol.2010.393">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734098053"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2473 class=n-a></a>Abdul-Fattah B, Al-Muriesh M, Huang CZ: Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum. <i>Dermatol Ther.</i> 2018; <b>31</b>(5): e12697. <a target=xrefwindow id=d14105e2481 href="http://www.ncbi.nlm.nih.gov/pubmed/30252999">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2484 href="https://doi.org/10.1111/dth.12697">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734098053">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d14105e2497 class=n-a></a>Thomas KS, Ormerod AD, Craig FE, <i> et al.</i>: Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. <i>J Am Acad Dermatol.</i> 2016; <b>75</b>(5): 940949. <a target=xrefwindow id=d14105e2508 href="http://www.ncbi.nlm.nih.gov/pubmed/27502313">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2511 href="https://doi.org/10.1016/j.jaad.2016.06.016">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d14105e2520 class=n-a></a>Ormerod AD, Thomas KS, Craig FE, <i> et al.</i>: Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. <i>BMJ.</i> 2015; <b>350</b>: h2958. <a target=xrefwindow id=d14105e2531 href="http://www.ncbi.nlm.nih.gov/pubmed/26071094">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2534 href="https://doi.org/10.1136/bmj.h2958">Publisher Full Text </a> | <a target=xrefwindow id=d14105e2538 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4469977">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d14105e2547 class=n-a></a>Bhat RM, Nandakishore B, Sequeira FF, <i> et al.</i>: Pyoderma gangrenosum: an Indian perspective. <i>Clin Exp Dermatol.</i> 2010; <b>36</b>(3): 2427. <a target=xrefwindow id=d14105e2558 href="http://www.ncbi.nlm.nih.gov/pubmed/21070329">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2561 href="https://doi.org/10.1111/j.1365-2230.2010.03941.x">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d14105e2570 class=n-a></a>Pereira N, Brites MM, Goncalo M, <i> et al.</i>: Pyoderma gangrenosum--a review of 24 cases observed over 10 years. <i>Int J Dermatol.</i> 2013; <b>52</b>(8): 93845. <a target=xrefwindow id=d14105e2581 href="http://www.ncbi.nlm.nih.gov/pubmed/23676016">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2584 href="https://doi.org/10.1111/j.1365-4632.2011.05451.x">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732757163"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2594 class=n-a></a>Partridge ACR, Bai JW, Rosen CF, <i> et al.</i>: Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. <i>Br J Dermatol.</i> 2018; <b>179</b>(2): 290295. <a target=xrefwindow id=d14105e2605 href="http://www.ncbi.nlm.nih.gov/pubmed/29478243">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2608 href="https://doi.org/10.1111/bjd.16485">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732757163">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d14105e2621 class=n-a></a>Brooklyn TN, Dunnill MG, Shetty A, <i> et al.</i>: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. <i>Gut.</i> 2006; <b>55</b>(4): 5059. <a target=xrefwindow id=d14105e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/16188920">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2635 href="https://doi.org/10.1136/gut.2005.074815">Publisher Full Text </a> | <a target=xrefwindow id=d14105e2639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1856164">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735544290"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2648 class=n-a></a>Diotallevi F, Campanati A, Radi G, <i> et al.</i>: Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature. <i>Dermatol Ther.</i> 2019; <b>32</b>(4): e12928. <a target=xrefwindow id=d14105e2659 href="http://www.ncbi.nlm.nih.gov/pubmed/30980454">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2662 href="https://doi.org/10.1111/dth.12928">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735544290">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734383329"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2675 class=n-a></a>Kochar B, Herfarth N, Mamie C, <i> et al.</i>: Tofacitinib for the Treatment of Pyoderma Gangrenosum. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(5): 991993. <a target=xrefwindow id=d14105e2686 href="http://www.ncbi.nlm.nih.gov/pubmed/30404036">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2689 href="https://doi.org/10.1016/j.cgh.2018.10.047">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734383329">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732885045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2702 class=n-a></a>Nasifoglu S, Heinrich B, Welzel J: Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. <i>Br J Dermatol.</i> 2018; <b>179</b>(2): 504505. <a target=xrefwindow id=d14105e2710 href="http://www.ncbi.nlm.nih.gov/pubmed/29451690">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2713 href="https://doi.org/10.1111/bjd.16468">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732885045">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735578857"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2726 class=n-a></a>Haag CK, Ortega-Loayza AG, Latour E, <i> et al.</i>: Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. <i>J Dermatolog Treat.</i> 2019; <b>18</b>: 14. <a target=xrefwindow id=d14105e2737 href="http://www.ncbi.nlm.nih.gov/pubmed/30998080">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2740 href="https://doi.org/10.1080/09546634.2019.1606888">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735578857">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727838531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2754 class=n-a></a>Song H, Lahood N, Mostaghimi A: Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. <i>Br J Dermatol.</i> 2018; <b>178</b>(2): 363368. <a target=xrefwindow id=d14105e2762 href="http://www.ncbi.nlm.nih.gov/pubmed/28742926">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2765 href="https://doi.org/10.1111/bjd.15850">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727838531">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d14105e2778 class=n-a></a>Nimmerjahn F, Ravetch JV: Anti-inflammatory actions of intravenous immunoglobulin. <i>Annu Rev Immunol.</i> 2008; <b>26</b>: 51333. <a target=xrefwindow id=d14105e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/18370923">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2789 href="https://doi.org/10.1146/annurev.immunol.26.021607.090232">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727692523"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2798 class=n-a></a>Laird ME, Tong LX, Lo Sicco KI, <i> et al.</i>: Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. <i>JAAD Case Rep.</i> 2017; <b>3</b>(3): 228229. <a target=xrefwindow id=d14105e2809 href="http://www.ncbi.nlm.nih.gov/pubmed/28443317">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2812 href="https://doi.org/10.1016/j.jdcr.2017.02.019">Publisher Full Text </a> | <a target=xrefwindow id=d14105e2816 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5394202">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727692523">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d14105e2829 class=n-a></a>Sharon V, Burrall B, Patel F, <i> et al.</i>: Multimodal therapy of idiopathic pyoderma gangrenosum. <i>Dermatol Online J.</i> 2014; <b>20</b>(6): pii: 13030/qt5s5397rd. <a target=xrefwindow id=d14105e2840 href="http://www.ncbi.nlm.nih.gov/pubmed/24945643">PubMed Abstract </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729281376"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14105e2849 class=n-a></a>Herskovitz I, MacQuhae FE, Dickerson JE Jr, <i> et al.</i>: Opioids' Effect on Healing of Venous Leg Ulcers. <i>J Invest Dermatol.</i> 2017; <b>137</b>(12): 26462649. <a target=xrefwindow id=d14105e2860 href="http://www.ncbi.nlm.nih.gov/pubmed/28842329">PubMed Abstract </a> | <a target=xrefwindow id=d14105e2863 href="https://doi.org/10.1016/j.jid.2017.07.837">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729281376">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2092/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2092/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada<br/> <sup>2</sup> Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada<br/> <sup>3</sup> Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, M5S 1B2, Canada<br/> <p> <div class=margin-bottom> Josh Fletcher <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Raed Alhusayen <br/> <span>Roles: </span> Writing  Review & Editing </div> <div class=margin-bottom> Afsaneh Alavi <br/> <span>Roles: </span> Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-2092/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 12 Dec 2019, 8:2092 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19909.1">https://doi.org/10.12688/f1000research.19909.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Fletcher J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21847 data-id=19909 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19909.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-2092/v1/pdf?article_uuid=0659ff69-fbdf-4bd9-b4d7-6da48d1991b8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19909.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Fletcher J, Alhusayen R and Alavi A. Recent advances in managing and understanding pyoderma gangrenosum [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):2092 (<a href="https://doi.org/10.12688/f1000research.19909.1" target=_blank>https://doi.org/10.12688/f1000research.19909.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19909 id=mobile-track-article-signin-19909 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19909?target=/articles/8-2092/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21847 /> <input name=articleId type=hidden value=19909 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Angelo Marzano</strong>, UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Alex Ortega</strong>, Department of Dermatology, Oregon Health & Science University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Dec 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-2092/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-2092/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61322-57771></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=61321-57772></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-2092/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>12 Dec 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Angelo Marzano</strong>, UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Alex Ortega</strong>, Department of Dermatology, Oregon Health & Science University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-2092/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-2092/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in managing and understanding...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-2092/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-2092/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-2092/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Fletcher J et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-2092/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-2092",
            templates : {
                twitter : "Recent advances in managing and understanding pyoderma gangrenosum. Fletcher J et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-2092/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in managing and understanding pyoderma gangrenosum", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in managing and understanding pyoderma gangrenosum", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19909/21847")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21847");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "57771": 0,
                           "57772": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "b9c50559-2f69-45d3-a4af-bc9c5dcb7278";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2092.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2092.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-2092.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-2092.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-2092.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>